Key result
Cardiac-specific overexpression of DGKzeta in transgenic mice completely blocked GPCR agonist-induced PKC translocation, ANF upregulation, and subsequent cardiac hypertrophy compared to wild-type mice.
Why the study?
Does cardiac-specific overexpression of DGKzeta prevent GPCR agonist-induced cardiac hypertrophy in mice?
Does cardiac-specific overexpression of DGKzeta prevent GPCR agonist-induced cardiac hypertrophy in mice?
Cardiac-specific overexpression of DGKzeta prevents GPCR agonist-induced cardiac hypertrophy in transgenic mice by regulating cellular diacylglycerol levels and PKC activity.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for DGKzeta modulation in hypertrophy; leaves open translation to human disease or therapy.
BACKGROUND: Diacylglycerol is a lipid second messenger that accumulates in cardiomyocytes when stimulated by Gqalpha protein-coupled receptor (GPCR) agonists such as angiotensin II, phenylephrine, and others. Diacylglycerol functions as a potent activator of protein kinase C (PKC) and is catalyzed by diacylglycerol kinase (DGK) to form phosphatidic acid and inactivated. However, the functional roles of DGK have not been previously examined in the heart. We hypothesized that DGK might prevent GPCR agonist-induced activation of diacylglycerol downstream signaling cascades and subsequent cardiac hypertrophy. METHODS AND RESULTS: To test this hypothesis, we generated transgenic (DGKzeta-TG) mice with cardiac-specific overexpression of DGKzeta. There were no differences in heart size and heart weight between DGKzeta-TG and wild-type littermate mice. The left ventricular function was normal in DGKzeta-TG mice. Continuous administration of subpressor doses of angiotensin II and phenylephrine caused PKC translocation, gene induction of atrial natriuretic factor, and subsequent cardiac hypertrophy in WT mice. However, in DGKzeta-TG mice, neither translocation of PKC nor upregulation of atrial natriuretic factor gene expression was observed after angiotensin II and phenylephrine infusion. Furthermore, in DGKzeta-TG mice, angiotensin II and phenylephrine failed to increase cross-sectional cardiomyocyte areas and heart to body weight ratios. Phenylephrine-induced increases in myocardial diacylglycerol levels were completely blocked in DGKzeta-TG mouse hearts, suggesting that DGKzeta regulated PKC activity by controlling cellular diacylglycerol levels. CONCLUSIONS: These results demonstrated the first evidence that DGKzeta negatively regulated the hypertrophic signaling cascade and resultant cardiac hypertrophy in response to GPCR agonists without detectable adverse effects in in vivo hearts.
No takes yet. Share an insight, caveat, or question.
Arimoto et al. (2005) studied Cardiac hypertrophy. Cardiac-specific overexpression of DGKzeta vs. Wild-type littermate mice was evaluated on GPCR agonist-induced cardiac hypertrophy (cross-sectional cardiomyocyte areas and heart to body weight ratios). Cardiac-specific overexpression of DGKzeta in transgenic mice completely blocked GPCR agonist-induced PKC translocation, ANF upregulation, and subsequent cardiac hypertrophy compared to wild-type mice.
Synapse has enriched 10 related papers. Consider them for comparative context: